Pharsight

ASTRAZENECA PATENTS FACING OPPOSITIONS

Top patents of ASTRAZENECA facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP2139494B1 11 Mar, 2020 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate Mar, 2028 6
EP2508188B1 10 May, 2023 Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate NA 5
EP2498759B1 01 Aug, 2018 Immediate release tablet formulations Nov, 2030 4
EP2056832B1 22 Mar, 2017 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate Aug, 2027 3
EP3769781B1 19 Apr, 2023 Stable anti-ifnar1 formulation Aug, 2036 1
EP2785349B2 09 Nov, 2022 Combination treatment of cancer Nov, 2032 1
EP3142661B1 06 Oct, 2021 Method for suppressing glucagon secretion of an sglt2 inhibitor May, 2035 1
EP3363807B1 13 Nov, 2019 Pharmaceutical composition comprising crystalline (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol (s)-propylene glycol solvate Jun, 2027 1
EP2498758B1 25 Jul, 2018 Bilayer tablet formulations Nov, 2030 1
EP3045466B1 06 Dec, 2017 (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol propylene glycol solvate as sgt2 inhibitor for the treatment of diabetes Jun, 2027 1
EP3009431B1 25 Oct, 2017 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer Jul, 2032 1